Treatment-related myelodysplastic syndrome: molecular characteristics and therapy.
Treatment-related myelodysplastic syndrome: molecular characteristics and therapy.
复制标题
DOI：
10.1097/moh.0b013e328343997a
复制
发表时间：
2011-03
影响因子：
3.2
通讯作者：
Deeg HJ
中科院分区：
文献类型：
--
作者：
Bhatia R;Deeg HJ
治疗相关骨髓增生异常综合征（t-MDS）是癌症治疗的严重并发症。在此，我们回顾了 t-MDS 危险因素、发病机制和治疗方面的最新进展。最近的研究提供了有关遗传风险因素的重要新信息，这些因素可能使个体患者在接触细胞毒性治疗药物后易患 t-MDS，并且可用于预测个体发生这种并发症的风险增加。还研究了与 t-MDS 发病机制中常见的遗传病变相关的特定候选基因的作用。最后，阐明了决定这种疾病移植治疗结果的因素。 HCT 为 t-MDS 提供了潜在的治愈疗法，但需要进一步改进才能改善结果。提高对遗传风险因素的了解有望促进早期识别有 t-MDS 风险的患者，指导治疗决策，并允许及早应用预防或治疗策略。
Treatment-related myelodysplastic syndrome (t-MDS) is a serious complication of cancer treatment. Here we review recent advances in knowledge of the risk factors, pathogenesis and treatment of t-MDS. Recent studies have provided important new information regarding genetic risk factors that may predispose individual patients to develop t-MDS after exposure to cytotoxic therapeutic agents and that may be used to predict individuals at enhanced risk for this complication. The role of specific candidate genes associated with commonly involved genetic lesions in the pathogenesis of t-MDS has also been investigated. Finally, factors determining outcomes of transplantation treatment for this disorder have been elucidated. HCT provides potentially curative therapy for t-MDS but additional improvements are necessary to improve outcomes. Improved understanding of genetic risk factors is expected to facilitate early identification of patients at risk for t-MDS, guiding therapeutic decision making, and allowing early application of preventive or therapeutic strategies.